TICAGRACE ASP

Description

TICAGRACE ASP Combikit of Ticagrelor Tablets 90mg & Aspirin Gastro-resistant 75mg TICAGRACE ASP is designed to provide a comprehensive antiplatelet therapy regimen for patients, particularly those at high risk of thrombotic events such as those with acute coronary syndrome (ACS) or a history of myocardial infarction. TICAGRACE ASP targets two different pathways of platelet activation to enhance the prevention of blood clots, offering a synergistic approach to reducing the risk of future cardiovascular events. Ticagrelor Mechanism of Action: Ticagrelor is a P2Y12 receptor antagonist that works by reversibly binding to P2Y12 receptors on platelets, inhibiting ADP-mediated platelet activation and aggregation. Indications: It is primarily indicated for the prevention of thrombotic events in patients with ACS or a history of myocardial infarction. Aspirin (Gastro-resistant) Mechanism of Action: Aspirin inhibits the cyclooxygenase (COX) enzyme, which results in the suppression of thromboxane A2 production, a substance that promotes platelet aggregation. The gastro-resistant formulation is designed to reduce gastrointestinal side effects by preventing the release of aspirin until it reaches the small intestine. Indications: Aspirin is used for its antiplatelet effects to reduce the risk of cardiovascular events in patients with coronary artery disease or after a heart attack or stroke. TICAGRACE ASP Convenience and Compliance: TICAGRACE ASP simplifies the regimen, potentially improving patient compliance by reducing the number of pills they need to take and ensuring the dosages are correctly matched. Clinical Benefit: TICAGRACE ASP is a cornerstone in the management of ACS and in the secondary prevention of cardiovascular events. The synergistic action of Ticagrelor and Aspirin offers superior protection against thrombosis compared to monotherapy with either agent.